XENICAL (Orlistat), Drug Insight and Market Forecast - 2032

“XENICAL (Orlistat), Drug Insight and Market Forecast - 2032” report provides comprehensive insights about XENICAL (Orlistat) for Obesity in the 7MM. A detailed picture of the XENICAL (Orlistat) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the XENICAL (Orlistat) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XENICAL (Orlistat) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

XENICAL (Orlistat) is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. It is indicated for obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet. It is also indicated to reduce the risk of weight regain after prior weight loss and for obese patients with an initial Body Mass Index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

The recommended dosage regimen is one 120 mg capsule three times a day with each main meal containing fat (during or up to 1 h after the meal). Patients should be advised to take a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat and also a multivitamin containing fat-soluble vitamins to ensure adequate nutrition.

Orlistat is a reversible inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the XENICAL (Orlistat) description, mechanism of action, dosage and administration, research and development activities in Obesity.
• Elaborated details on XENICAL (Orlistat) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XENICAL (Orlistat) research and development activity in Obesity in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XENICAL (Orlistat).
• The report contains forecasted sales of XENICAL (Orlistat) for Obesity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Obesity.
• The report also features the SWOT analysis with analyst views for XENICAL (Orlistat) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XENICAL (Orlistat) Analytical Perspective

In-depth XENICAL (Orlistat) Market Assessment

This report provides a detailed market assessment of XENICAL (Orlistat) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

XENICAL (Orlistat) Clinical Assessment

The report provides the clinical trials information of XENICAL (Orlistat) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XENICAL (Orlistat) dominance.
• Other emerging products for Obesity are expected to give tough market competition to XENICAL (Orlistat) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XENICAL (Orlistat) in Obesity.
• The in-depth analysis of the forecasted sales data of XENICAL (Orlistat) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XENICAL (Orlistat) in Obesity.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of XENICAL (Orlistat)?
• What is the clinical trial status of the study related to XENICAL (Orlistat) in Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XENICAL (Orlistat) development?
• What are the key designations that have been granted to XENICAL (Orlistat) for Obesity?
• What is the forecasted market scenario of XENICAL (Orlistat) for Obesity?
• What are the forecasted sales of XENICAL (Orlistat) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Obesity and how are they giving competition to XENICAL (Orlistat) for Obesity?
• Which are the late-stage emerging therapies under development for the treatment of Obesity?

This product will be delivered within 2 business days.